Cancers in France in 2015 attributable to occupational exposures.

Carcinogens / toxicity Female France / epidemiology Humans Male Neoplasms / chemically induced Occupational Exposure / adverse effects
Cancer Carcinogen Comparative risk assessment/attributable fractions Occupation Risk

Journal

International journal of hygiene and environmental health
ISSN: 1618-131X
Titre abrégé: Int J Hyg Environ Health
Pays: Germany
ID NLM: 100898843

Informations de publication

Date de publication:
01 2019
Historique:
received: 24 04 2018
revised: 19 07 2018
accepted: 27 07 2018
pubmed: 4 9 2018
medline: 7 8 2019
entrez: 4 9 2018
Statut: ppublish

Résumé

Recent and comprehensive estimates for the number of new cancer cases in France attributable to occupational exposures are lacking. To estimate the number of new cancer cases attributable to occupational exposures, using a newly developed methodology and the most recent data, for a comprehensive set of occupational carcinogens in France in 2015. Surveys among employees, the national labor force data, a cohort of agricultural workers, national monitoring of workers exposed to ionizing radiation and job-exposure matrix in France were used. The number and proportion of new cancer cases attributable to established occupational carcinogens (Group 1) was estimated using estimation of lifetime exposure and risk estimates from cohort studies. Cancer data were obtained from the French Cancer Registries Network. In France in 2015, an estimated 7905 new cancer cases, 7336 among men and 569 among women, were attributable to occupational exposures, representing 2.3% of all new cancer cases (3.9% and 0.4% among men and women respectively). Among men and women, lung cancer was impacted the most, followed by mesothelioma and bladder cancer in men, and by mesothelioma and ovary in women. These cancers contributed to 89% of the total cancers attributable to occupational carcinogens in men, and to 80% in women. The main contributing occupational agent was asbestos among men (45%) and women (60%). Currently, occupational exposures contribute to a substantial burden of cancer in France. Enhanced monitoring and implementation of protective labor policies could potentially prevent a large proportion of these cancers.

Sections du résumé

BACKGROUND
Recent and comprehensive estimates for the number of new cancer cases in France attributable to occupational exposures are lacking.
OBJECTIVES
To estimate the number of new cancer cases attributable to occupational exposures, using a newly developed methodology and the most recent data, for a comprehensive set of occupational carcinogens in France in 2015.
METHODS
Surveys among employees, the national labor force data, a cohort of agricultural workers, national monitoring of workers exposed to ionizing radiation and job-exposure matrix in France were used. The number and proportion of new cancer cases attributable to established occupational carcinogens (Group 1) was estimated using estimation of lifetime exposure and risk estimates from cohort studies. Cancer data were obtained from the French Cancer Registries Network.
RESULTS
In France in 2015, an estimated 7905 new cancer cases, 7336 among men and 569 among women, were attributable to occupational exposures, representing 2.3% of all new cancer cases (3.9% and 0.4% among men and women respectively). Among men and women, lung cancer was impacted the most, followed by mesothelioma and bladder cancer in men, and by mesothelioma and ovary in women. These cancers contributed to 89% of the total cancers attributable to occupational carcinogens in men, and to 80% in women. The main contributing occupational agent was asbestos among men (45%) and women (60%).
CONCLUSIONS
Currently, occupational exposures contribute to a substantial burden of cancer in France. Enhanced monitoring and implementation of protective labor policies could potentially prevent a large proportion of these cancers.

Identifiants

DOI: 10.1016/j.ijheh.2018.07.015 PMID: 30174219
pubmed: 30174219
pii: S1438-4639(18)30326-2
doi: 10.1016/j.ijheh.2018.07.015
pii:
doi:

Substances chimiques

Carcinogens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

22-29

Informations de copyright

Copyright © 2018. Published by Elsevier GmbH.

Auteurs

Claire Marant Micallef (C)

Section of Cancer Surveillance, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon, CEDEX 08, France. Electronic address: marantmicallefc@iarc.fr.

Kevin D Shield (KD)

Section of Cancer Surveillance, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon, CEDEX 08, France. Electronic address: kevin.david.shield@gmail.com.

Jérôme Vignat (J)

Section of Cancer Surveillance, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon, CEDEX 08, France. Electronic address: vignatj@iarc.fr.

Isabelle Baldi (I)

Equipe Santé Environnement, Centre de recherche INSERM U 897, Université de Bordeaux, Bât. ISPED - Case 11, 146, rue Léo-Saignat, Bordeaux, France. Electronic address: isabelle.baldi@u-bordeaux.fr.

Barbara Charbotel (B)

Université Lyon 1, UMRESTTE, UMR_T9405, Service des maladies professionnelles, Hospices Civils de Lyon, 8, avenue Rockefeller, 69008, Lyon, France. Electronic address: barbara.charbotel-coing-boyat@univ-lyon1.fr.

Béatrice Fervers (B)

Centre Léon Bérard, Université de Lyon, Département cancer environnement, 28 rue Laennec, 69008, Lyon, France. Electronic address: beatrice.fervers@lyon.unicancer.fr.

Anabelle Gilg Soit Ilg (A)

Santé publique France, Direction Santé Travail, 12, rue du Val d'Osne, 94 415, Saint-Maurice cedex, France. Electronic address: Anabelle.GILGSOITILG@santepubliquefrance.fr.

Pascal Guénel (P)

Centre de recherche en Epidémiologie et Santé des Populations (CESP), Cancer and Environment team, Université Paris-Sud, Université Paris-Saclay, 16, avenue Paul Vaillant Couturier, 94800, Villejuif, France. Electronic address: pascal.guenel@inserm.fr.

Ann Olsson (A)

Section of Environment and Radiation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon, CEDEX 08, France. Electronic address: olssona@iarc.fr.

Lesley Rushton (L)

Department of Epidemiology and Biostatistics, Imperial College London, Level 2, Faculty Building, South Kensington Campus, London, SW7 2AZ, United Kingdom. Electronic address: l.rushton@imperial.ac.uk.

Sally J Hutchings (SJ)

Manchester University, Population Health, Health Services Research & Primary Care, School of Health Sciences, University of Manchester, Oxford Road, Manchester, M13 9PL, UK. Electronic address: sally.hutchings@postgrad.manchester.ac.uk.

Enora Cléro (E)

Direction of Health and Environment, Institute for Radiological Protection and Nuclear Safety, 31, avenue de la Division Leclerc 92260, Fontenay-aux-Roses, 92260, France. Electronic address: enora.clero@irsn.fr.

Dominique Laurier (D)

Direction of Health and Environment, Institute for Radiological Protection and Nuclear Safety, 31, avenue de la Division Leclerc 92260, Fontenay-aux-Roses, 92260, France. Electronic address: dominique.laurier@irsn.fr.

Pascale Scanff (P)

Direction of Health and Environment, Institute for Radiological Protection and Nuclear Safety, 31, avenue de la Division Leclerc 92260, Fontenay-aux-Roses, 92260, France. Electronic address: pascale.scanff@irsn.fr.

Freddie Bray (F)

Section of Cancer Surveillance, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon, CEDEX 08, France. Electronic address: brayf@iarc.fr.

Kurt Straif (K)

Section of Evidence Synthesis and Classification, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon, CEDEX 08, France. Electronic address: straifk@iarc.fr.

Isabelle Soerjomataram (I)

Section of Cancer Surveillance, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon, CEDEX 08, France. Electronic address: SoerjomataramI@iarc.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions toxiques › Noxas › Cancérogènes › Cancers in France in 2015 attributable to...
questionsmedicales.fr › Régions géographiques › Europe › France › Cancers in France in 2015 attributable to...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Cancers in France in 2015 attributable to...
questionsmedicales.fr › Tumeurs › Cancers in France in 2015 attributable to...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pollution de l'environnement › Exposition environnementale › Exposition professionnelle › Cancers in France in 2015 attributable to...